Funding Opportunity RFA-AG-19-007 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Edward R. Roybal Centers for translational intervention development research for Alzheimers Disease and Alzheimers Disease related dementias care provider support. The purpose of the Roybal Centers is to develop behavioral interventions that improve the health, well-being and/or capacity of individuals and/or systems that provide care to persons with AD-ADRD. Roybal Centers will conduct Stage 0 through IV pilot studies in accordance with the multidirectional, translational NIH Stage Model, to produce potent and implementable principle-driven behavioral interventions.

Funding Opportunity RFA-AG-19-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Edward R. Roybal Centers for Translation Research in the Behavioral and Social Sciences of Aging. The purpose of the Roybal Centers is to develop behavioral interventions that improve the health and well-being of people as they are aging and the capacity of institutions to adapt to societal aging. Roybal Centers will conduct Stage 0 through IV pilot studies in accordance with the multidirectional, translational NIH Stage Model, to produce potent and implementable principle-driven behavioral interventions.

Funding Opportunity PAR-18-820 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, mechanisms of drug action, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies, or discovery activities such as high throughput screening and hit optimization.

Funding Opportunity PAR-18-822 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical and preclinical/non-clinical research to improve our understanding of disease mechanisms in tuberculosis meningitis (TBM) and to improve therapy in the presence or absence of human immunodeficiency virus (HIV) co-infection.

Funding Opportunity PA-18-819 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages the translation of technologies for brain or behavioral research from academic and other non-small business research sectors to the marketplace. Encouraged from Small Business Concerns (SBCs) are Small Business Innovation Research (SBIR) grant applications that propose to further develop, make more robust, and make more user-friendly such technologies in preparation for commercial dissemination. It is expected that this activity will require partnerships and close collaboration between the original developers of these technologies and SBCs, which may be accomplished in any of a number of ways, including the use of multiple program directors/principal investigators.

Negotiable: Paramount Recruitment: Bioinformatician Cambridge Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100, Cambridge, England

Negotiable: Paramount Recruitment: Web Developer - Genomics Cambridge Paramount are working in partnership with Genomics England to expand their team in order to deliver success with t Cambridge, England

The preferred candidate should have:. The Department promoted growth of research and education with recognized programs in orthopedics, rehabilitation...
From Indeed - Wed, 06 Jun 2018 14:44:31 GMT - View all Milwaukee, WI jobs

Funding Opportunity PA-18-818 from the NIH Guide for Grants and Contracts. The reproducibility and comparability of research on dietary supplements is enhanced by rigorous analytical characterization of key experimental materials and the publication of validated analytical methods that accurately and precisely characterized and quantify constituents in dietary supplement ingredients and products. This FOA builds on existing NIH awards to support the performance and publication of formal single-laboratory validation studies of quantitative analytical methods. The methods proposed for validation must be used to identify and quantify dietary supplement-relevant chemical constituents (i.e., active or marker chemical compounds, adulterants, contaminants) or their metabolites in experimental reagents, raw materials, and/or clinical specimens (for example urine or plasma samples). Methods must have been developed or utilized in fulfillment of the active parent grants specific aims. Candidate constituents for quantitative method validation studies include (but are not limited to): phytochemicals, nutrients, and potentially deleterious substances such as pesticides and mycotoxins. Multi-laboratory validation studies will not be supported through this FOA.

Notice NOT-HL-18-631 from the NIH Guide for Grants and Contracts

Notice NOT-DE-18-019 from the NIH Guide for Grants and Contracts

Notice NOT-EB-18-018 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-185 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-18-817 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) announces the availability of administrative supplements to support research in which the supplemental funding would investigate the role of dietary supplements and/or their ingredients in health maintenance and disease prevention. Parent awards need not be focused on dietary supplements; this FOA may provide support to include dietary supplements within the scope of relevant research projects. Research interests of ODS are not limited to specific health conditions, organ systems or population groups. ODS supports all types of research, including pre-clinical, clinical, behavioral, and epidemiological. Additionally, ODS supports research and training programs that build future research capacity for studying the role of dietary supplements in health and disease prevention. Primary consideration for support will be given to applications that stimulate dietary supplement research where it is lacking or lagging, clarify gaps, opportunities and balance between benefits and risks where data are in conflict, target special population groups where additional science on dietary supplements is needed, and focus on the use of dietary supplements in improving or maintaining health and reducing the risk of chronic disease. This FOA will not support new clinical trials.

Funding Opportunity PA-18-815 from the NIH Guide for Grants and Contracts. Fetal bovine serum (FBS) is the most widely used growth supplement for cell culture because it cost-effectively supports the survival and growth of many cell lines. Although serum is an effective growth promotor, it is highly variable in its composition, activity, and physiological effects on cells. This variability introduces inconsistencies into cell culture research. This Funding Opportunity Announcement (FOA) will support SBIR projects to develop novel, reliable, and cost-effective tools that will make it easier for researchers to standardize or replace serum in cell culture.

Funding Opportunity PA-18-816 from the NIH Guide for Grants and Contracts. Fetal bovine serum (FBS) is the most widely used growth supplement for cell culture because it cost-effectively supports the survival and growth of many cell lines. Although serum is an effective growth promotor, it is highly variable in its composition, activity, and physiological effects on cells. This variability introduces inconsistencies into cell culture research. This Funding Opportunity Announcement (FOA) will support STTR projects to develop novel, reliable, and cost-effective tools that will make it easier for researchers to standardize or replace serum in cell culture.

Negotiable: Paramount Recruitment: Scientist - Computational Biology/Bioinformatics Data Science, Human Genetics, Omics - Permanent Competitive salary, generous relocation package, great work-life balance! A fantastic, challenging new opportunity has become available with a Top Pharmac Biberach an der Riß, Germany

Act as a liaison to the bioinformatics team to provide feedback on the quality of sequencing from new preparations....
From Medical College of Wisconsin - Mon, 04 Jun 2018 21:08:48 GMT - View all Milwaukee, WI jobs

Negotiable: Paramount Recruitment: Scientific Curator 100,000 Genomes Project - Bioinformatics - Central London OR Cambridge! Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100,000 Genomes Project. London, England

Notice NOT-MD-18-006 from the NIH Guide for Grants and Contracts